Medicine Recommendations

Gender Dysphoria

Osteoarthritis

Psoriasis

Acute Gout (as per LSCMMG Guidelines)

For replacement therapy of adrenal insufficiency in children and adolescents (from birth to <18 years old)

Treatment of adrenal insufficiency in adults.

Treatment of mild non-infectious allergic or inflammatory conjunctival diseases

Treatment of essential thrombocythemia or polycythaemia vera with a high risk for thromboembolic complications

Psoriasis

The prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults suffering from symptomatic Sickle Cell Syndrome

Rheumatoid conditions, lupus erythematosus, dermatological conditions

Hypersalivation

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.

Treatment of post menopausal osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures

Postmenopausal osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures

Osteoporosis (NICE TA464)

NICE TA464 - Bisphosphonates for treating osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures

Acute Gout (as per LSCMMG Guidelines)

MHRA Drug Safety Update - High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks

MHRA Drug Safety Update - NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks

Pain

MHRA Drug Safety Update - High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks

MHRA Drug Safety Update - NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks

For adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding

Raynauds

Depressive illness